In­cyte wins ac­cel­er­at­ed ap­proval for PD-1 in rare skin can­cer

In­cyte tout­ed an ac­cel­er­at­ed ap­proval for its PD-1 reti­fan­limab in a rare skin can­cer on Wednes­day, rough­ly a year and a half af­ter the drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.